Algernon Pharmaceuticals 

Algernon Pharmaceuticals Inc. is a biopharmaceutical firm actively engaged in drug development at the clinical trial stage. Its therapeutic endeavors span a range of challenging medical conditions, including non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF), persistent cough, and acute lung damage linked to COVID-19, with operations primarily in Canada and Australia. Their flagship investigational drug, NP-120, functions as an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist. This compound specifically targets the NMDA-type subunit 2B (Glu2NB) and concurrently acts as an agonist for the Sigma-1 receptor, a crucial chaperone protein whose expression is heightened during endoplasmic reticulum stress. Additionally, Algernon is advancing AP-188, a psychedelic agent from the tryptamine class, for treating ischemic stroke in human patients. To support its stroke clinical research program for AP-188, the company has established a collaboration with Charles River Laboratories for preclinical investigations. Established in 2015, the firm maintains its principal office in Vancouver, Canada.